Response to: “Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication”

Jonathan W. Rick, Peter Lio, Jennifer L. Hsiao, Vivian Y. Shi*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)e33-e34
JournalJournal of the American Academy of Dermatology
Issue number1
StatePublished - Jul 2022

ASJC Scopus subject areas

  • Dermatology

Cite this